ADMA Biologics shares fell 29% on April 6 due to claims of 'channel stuffing'. On the same day, law firm Bleichmar Fonti & Auld LLP launched an investigation into potential federal securities law violations. Investors are urged to contact the law firm regarding a potential class action lawsuit.
